Showing results (2311-2320 of 3,026) with videos related to

Sort By:
Pageof 303
Current Pharmaceutical Biotechnology|May 11, 2011
The effect of critical illness on drug distributionDaniel Gonzalez, Daniela J Conrado, Ursula Theuretzbacher, et al.
Current Pharmaceutical Biotechnology|May 25, 2011
Apoptotic potency of angiostatic compounds in the treatment of cancerEsther Raskopf, Tilman Sauerbruch, Volker Schmitz
Current Pharmaceutical Biotechnology|May 25, 2011
Biomarkers for hepatocellular apoptosis in the management of liver diseasesMarie V St-Pierre, Jean-Francois Dufour
Current Pharmaceutical Biotechnology|April 8, 2011
Combined light and electron microscopy using diaminobenzidine photooxidation to monitor trafficking of lipids derived from lipoprotein particlesClemens Röhrl, Claudia Meisslitzer-Ruppitsch, Robert Bittman, et al.
Current Pharmaceutical Biotechnology|April 8, 2011
Tumor vasculature targeting through NGR peptide-based drug delivery systemsAngelo Corti, Flavio Curnis
Current Pharmaceutical Biotechnology|April 8, 2011
Dermaseptins as models for the elucidation of membrane-acting helical amphipathic antimicrobial peptidesMohamed Amiche, Cécile Galanth
Current Pharmaceutical Biotechnology|April 8, 2011
Statins in the treatment of acute ischemic strokeFabrizio Montecucco, Alessandra Quercioli, Marisol Mirabelli-Badenier, et al.
Current Pharmaceutical Biotechnology|April 8, 2011
Immunosuppressive treatments in acute myocardial infarction and strokeLizzia Raffaghello, Giovanna Bianchi, Vito Pistoia
Current Pharmaceutical Biotechnology|April 8, 2011
Roles of connexins in atherosclerosis and ischemia-reperfusion injurySandrine Morel, Brenda R Kwak
Current Pharmaceutical Biotechnology|June 11, 2011
Modeling Follicle Stimulating Hormone (FSH) levels in serum for controlled ovarian hyperstimulation II: the underlying mechanismsDavid H McCulloh, Jose M Colon, Peter G McGovern
Pageof 303